We understand that people with cancer are worried about coronavirus. Here is the latest guidance. We will update it regularly.

Publication Details

Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm
Future treatments in acute myeloid leukaemia (AML). A guide for patients

Future treatments in acute myeloid leukaemia (AML). A guide for patients (October 2018)

The main treatment for acute myeloid leukaemia (AML) is chemotherapy, including targeted therapy. This might be followed by a stem cell transplant, and surgery and radiotherapy may be used in special circumstances. New therapies are being developed and investigated and this booklet describes several of these: clofarabine (DNA synthesis inhibitor); gilteritinib and quizartinib (tyrosine kinase inhibitors); venetoclax (B-cell lymphoma-2 (BCL2) inhibitor); and Vyxeos® (a combination of daunorubicin and cytarabine. 

Author(s)
Leukaemia Care
Place of publication
Worcester
Publisher
Date of publication
October 2018
Pages
36pp
Price
Free.
Format
Booklet
Language
English
Download this resource
Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm